Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Siwen Hu-LieskovanFadi BraitehJuneko E Grilley OlsonXiao WangAlison ForgieVinicius BonatoIra A JacobsJeffrey ChouMelissa Lynne JohnsonPublished in: Targeted oncology (2021)
ClinicalTrials.gov identifier NCT02573259; registered October 2015.
Keyphrases